All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-12-17T12:34:05.000Z

QUAZAR: Should maintenance with CC-486 become standard of care following induction chemotherapy?

Featured
Dec 17, 2019
Share:

Bookmark this article

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Andrew Wei, The Alfred Hospital, Victoria, AU about the results of the phase III QUAZAR AML-001 study. The QUAZAR study investigated the use of CC-486 as maintenance therapy in patients with acute myeloid leukemia (AML) who are in first remission following induction chemotherapy (with or without consolidation).

CC-486 is an orally administered hypomethylating agent which, since it can be given for longer per-cycle, has a longer duration of exposure than previously investigated agents. Dr Wei highlights that this is the first study to show a clinical benefit of maintenance therapy in patients with AML in first remission and anticipates this will lead to a change in the current standard of care treatment.

QUAZAR: Should maintenance with CC-486 become standard of care following induction chemotherapy?

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox